GervanoRA Announced the Release of Opportunity Assessment Report Titled “Aggressive Large B-cell Lymphoma Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2018”

GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Aggressive Large B-cell Lymphoma Pipeline Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics, and Pipeline Analysis H2 2018.

GervanoRA’s pipeline analysis and opportunity assessment report “Aggressive Large B-cell Lymphoma: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis, H2 2018” analyzed and assessed Aggressive Large B-cell Lymphoma pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Aggressive Large B-cell Lymphoma industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
• Unmet needs and Opportunities
• Epidemiology and Epidemiology forecast 2019 – 2025
• Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
• Patent Analysis of Pipeline Molecules
• Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
• Clinical Trials Summary
• Current and Future Competitive Landscape
• Key Company Profiles with SWOT Analysis
• Emerging Company Profiles with Opportunity Assessments
• Pipeline Drug Descriptions along with Development milestones (Past and Future)
• University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. METHODOLOGY
1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
1.4. ABOUT US: GERVANORA DATA SERVICES
2. EXECUTIVE SUMMARY
2.1. REPORT MAJOR FINDINGS
2.2. KEY EVENTS IN AGGRESSIVE LARGE B-CELL LYMPHOMA COMPETITIVE SPACE
3. DISEASE OVERVIEW
3.1. DISEASE DEFINITION & SYMPTOMS
3.1.1. CLINICAL MANIFESTATIONS
3.1.2. PATHOGENESIS
3.2. DISEASE CAUSE AND CLASSIFICATION
3.3. DISEASE DIAGNOSIS
3.4. TREATMENT ALGORITHM AND GUIDELINES
3.5. EPIDEMIOLOGY AND DISEASE BURDEN
3.6. EPIDEMIOLOGY FORECAST
3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
4. MARKET DYNAMICS
4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
4.2. PRICING AND REIMBURSEMENT
4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
4.5. NEW DRUG APPROVALS (EX-US) SINCE 2010
4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
5. PIPELINE ANALYSIS
5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
5.1.1. AGGRESSIVE LARGE B-CELL LYMPHOMA PHASE 3 MOLECULES
5.1.2. AGGRESSIVE LARGE B-CELL LYMPHOMA PHASE 2 MOLECULES
5.1.3. AGGRESSIVE LARGE B-CELL LYMPHOMA PHASE 1 MOLECULES
5.1.4. AGGRESSIVE LARGE B-CELL LYMPHOMA PRECLINICAL MOLECULES
5.1.5. AGGRESSIVE LARGE B-CELL LYMPHOMA EARLY R&D MOLECULES
5.1.6. AGGRESSIVE LARGE B-CELL LYMPHOMA INACTIVE AND DISCONTINUED MOLECULES
5.2. PIPELINE ANALYSIS BY GEOGRAPHY
5.2.1. UNMET NEEDS AND OPPORTUNITIES
5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
5.3.1. UNMET NEEDS AND OPPORTUNITIES
5.4. PIPELINE ANALYSIS BY DRUG CLASS
5.4.1. UNMET NEEDS AND OPPORTUNITIES
5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
5.5.1. UNMET NEEDS AND OPPORTUNITIES
5.6. PIPELINE MOLECULES BY UNIVERSITIES AND INSTITUTES
6 ESTIMATED APPROVAL TIMELINE
6.1.1. METHODOLOGY
6.1.2. ESTIMATED APPROVAL TIME LINES US & EX-US
7. AGGRESSIVE LARGE B-CELL LYMPHOMA CLINICAL TRIALS SUMMARY
7.1. AGGRESSIVE LARGE B-CELL LYMPHOMA PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
7.1.1. KEY PHASE 3 RESULTS
7.1.2. KEY PHASE 2 RESULTS
7.2. ONGOING CLINICAL TRIALS SUMMARY
7.2.1 KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
7.2.2 KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
7.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
7.3. PLANNED CLINICAL TRIALS SUMMARY
7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
7.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
7.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
7.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY
8. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
8.1. COMPANIES
8.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
8.1.2. TOP 20 EMERGING COMPANIES IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA AREA
8.3. UNIVERSITIES AND INSTITUTES – LICENSING OPPORTUNITIES
9. ABBREVIATIONS

LIST OF TABLES:

TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
TABLE 02: DISEASE EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
TABLE 03: MAJOR COLLABORATIVE AGREEMENTS IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA AREA
TABLE 04: MAJOR LICENSING AGREEMENTS IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA AREA
TABLE 05: MAJOR MERGERS AND ACQUISITIONS IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA AREA
TABLE 06: MAJOR ALLIANCE AGREEMENTS IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA AREA
TABLE 07: MAJOR FINANCING DEALS IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA AREA
TABLE 08: MAJOR DEALS IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA AREA RANKED BY DEAL AMOUNT
TABLE 09: US FDA APPROVED DRUGS SINCE 2010
TABLE 10: EX-US APPROVED DRUGS SINCE 2010
TABLE 11: PHASE 3 MOLECULES IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA DRUG PIPELINE
TABLE 12: PHASE 2 MOLECULES IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA DRUG PIPELINE
TABLE 13: PHASE 1 MOLECULES IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA DRUG PIPELINE
TABLE 14: PRECLINICAL MOLECULES IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA DRUG PIPELINE
TABLE 15: EARLY R&D MOLECULES IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA DRUG PIPELINE
TABLE 16: INACTIVE AND DISCONTINUED MOLECULES IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA DRUG PIPELINE
TABLE 17: AGGRESSIVE LARGE B-CELL LYMPHOMA PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION
TABLE 18: AGGRESSIVE LARGE B-CELL LYMPHOMA PIPELINE MOLECULES OVERVIEW BY DRUG CLASS
TABLE 19: AGGRESSIVE LARGE B-CELL LYMPHOMA PIPELINE MOLECULES BY UNIVERSITIES
TABLE 20: AGGRESSIVE LARGE B-CELL LYMPHOMA PIPELINE MOLECULES BY INSTITUTES
TABLE 21: ESTIMATED APPROVAL Time lines OF PIPELINE MOLECULES
TABLE 22: KEY PHASE 3 ONGOING CLINICAL TRIALS
TABLE 23: KEY PHASE 2 ONGOING CLINICAL TRIALS
TABLE 24: KEY PHASE 1 ONGOING CLINICAL TRIALS
TABLE 25: PLANNED CLINICAL TRIALS FOR THE AGGRESSIVE LARGE B-CELL LYMPHOMA AREA
TABLE 26: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
TABLE 27: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
TABLE 28: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
TABLE 29: ESTABLISHED COMPANIES SCENARIO
TABLE 30: LIST OF EMERGING COMPANIES IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA AREA
TABLE 31: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
TABLE 32: COMPETITIVE OPPORTUNITIES, INSTITUTES
(Above mentioned tables are a few among the total 87 tables in the report)

LIST OF FIGURES:

FIGURE 01: KEY PIPELINE EVENTS, 2019-2029
FIGURE 02: AGGRESSIVE LARGE B-CELL LYMPHOMA EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
FIGURE 03: OVERALL DEALS ACTIVITY IN THE AGGRESSIVE LARGE B-CELL LYMPHOMA AREA
FIGURE 04: OVERALL DEAL FINANCING ACTIVITY V/S DEAL TYPE
FIGURE 05: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
FIGURE 06: AGGRESSIVE LARGE B-CELL LYMPHOMA DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
FIGURE 07: AGGRESSIVE LARGE B-CELL LYMPHOMA DRUG PIPELINE ANALYSIS BY GEOGRAPHY
FIGURE 08: AGGRESSIVE LARGE B-CELL LYMPHOMA DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
FIGURE 09: AGGRESSIVE LARGE B-CELL LYMPHOMA DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 10: AGGRESSIVE LARGE B-CELL LYMPHOMA DRUG PIPELINE ANALYSIS BY DRUG CLASS
FIGURE 11: AGGRESSIVE LARGE B-CELL LYMPHOMA PIPELINE MOLECULES DEVELOPED BY UNIVERSITIES AND INSTITUTES
FIGURE 12: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 13: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 14: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
FIGURE 15: COMPANY FINANCIAL INFORMATION
FIGURE 16: COMPANY SWOT ANALYSIS
(Above mentioned figures are a few among the total 51 figures in the report)

This report is available on promotional basis.

To view sample report: www.gervanora.com/request-for-sample-report/

Why Choose GervanoRA??

GervanoRA is working dedicatedly for healthcare (Pharma & Medical Device) domain to empower our client’s business by assisting them in decision making with our wealthiness of database, expertise in analytics, and domain experts.

Vast & Tailor-made Database: GervanoRA utilizes its in-built rich database of pharmaceutical sector and Medical device sector to help our clients with their bespoke requirements. We have databases of Pharma Pipeline Drugs, Pharma News, Pharma Deals and Pipeline Medical Devices, Medical Device News and Medical Device Deal.

Coverage: We cover almost all major countries on the globe by providing Pharma & Medical device pipeline insights along with epidemiology, epidemiology forecast, Patent analysis, Insights on clinical trials and emerging opportunities. Using our database analytics, we are cracking the future numbers to assess market opportunities in healthcare domain.

Resources to meet the Goals: We have great number of experts, Analysts, Senior Researchers and Researchers to take care of our dynamic day to day process, like building database, updating the database, optimizing primary inputs, using internal tools analytics, Conducting KOL Interviews and Gathering field intelligence through paid surveys in all healthcare markets.

About GervanoRA:

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports and consulting services, based in Goa, India. GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we are playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations (KOLs) to garner valuable key insights.

To assist our global clients to attain their segment and sub segment specific goals, we are enlightening them on domain specific live updates through our GervanoRA 360 Degree PharmMedTech Monthly Bulletin (Monthly Report) which serve our clients with bespoke requirements without missing any live update for the particular month, as we know how valuable it is to be stayed updated with day to day dynamic industry sectors.

GervanoRA Data Services LLP
Goa IT Innovation Centre,
Goa Chamber of Commerce and Industry Bldg, 2nd Floor, S-2 Block,
Opp: Hyundai Showroom, Verna, South Goa,
Goa INDIA 403722
Email: sales@gervanora.com

This release was published on openPR.